Indian companies eye $1billion generic opportunity

It's literally a billion-dollar opportunity. In the wake of patent expiries on three blockbuster drugs over the last six-seven months, an opportunity worth nearly $1.3 billion is up for grabs for domestic generic players.

Read Full Story>>